Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Selinexor Again Shows Promise in Heavily Pretreated Myeloma

May 2nd 2018

Selinexor induced an overall response rate of 25.4% in patients with penta-refractory multiple myeloma, according to top-line results from part 2 of the phase IIb STORM trial.

Dr. Wolf Discusses High-Risk Multiple Myeloma

May 2nd 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.

Dr. Usmani on PD-1/PD-L1 Inhibitors in Hematologic Malignancies

April 30th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the evolution of PD-1/PD-L1 inhibitors in the treatment of patients with hematologic malignancies.

European Panel Backs Carfilzomib Label Update in Myeloma

April 30th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding final overall survival data from the phase III ASPIRE trial to the label for carfilzomib for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

April 28th 2018

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Expert Explains Shifting Myeloma Paradigm

April 27th 2018

Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.

Options Continue to Emerge for Transplant-Ineligible Multiple Myeloma

April 26th 2018

Nitya Nathwani, MD, highlights current treatment options for transplant-ineligible multiple myeloma, as well as combinations on the horizon.

Dr. Usmani on Minimal Residual Disease in Multiple Myeloma

April 25th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the impact of minimal residual disease (MRD) on clinical practice.

Dr. Bergsagel on Competing Philosophies of Treatment in Patients With Relapsed Myeloma

April 24th 2018

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses competing strategies in treating patients with relapsed multiple myeloma.

Dr. Htut on CAR T-Cell Therapy in Patients With Multiple Myeloma

April 24th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Landgren Explains Evolving Myeloma Landscape

April 20th 2018

C. Ola Landgren, MD, PhD, shares his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

April 20th 2018

Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.

Dr. Wolf on the Treatment of High-Risk Patients With Multiple Myeloma

April 20th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.

Fonseca Discusses Integrating Biology and Treatment in Multiple Myeloma

April 19th 2018

Rafael Fonseca, MD, discusses the integration of biology and treatment selection for patients with newly diagnosed multiple myeloma.

Triplets Reign Supreme in Relapsed/Refractory Myeloma

April 18th 2018

Leif Bergsagel, MD, discusses the treatment evolution for patients with relapsed/refractory multiple myeloma.

Dr. Stewart on the Role of Transplant in Multiple Myeloma

April 13th 2018

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Dr. Fonseca on FISH Testing in Patients With Myeloma

April 10th 2018

Rafael Fonseca, MD, hematologist, Mayo Clinic, discusses the use of fluorescence in situ hybridization (FISH) in diagnosing patients with myeloma.

Dr. van Besien on Autologous Stem Cell Transplantation in Hematologic Malignancies

April 4th 2018

Koen van Besien, MD, PhD, director, Stem Cell Transplant Program, professor of medicine, Weill Cornell Medical College, attending physician, NewYork-Presbyterian Hospital, discusses use of autologous stem cell transplantation in large cell lymphoma and multiple myeloma.

Dr. Lonial Discusses Novel Agents in Multiple Myeloma

April 3rd 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses novel agents for the treatment of patients with multiple myeloma.

Denosumab Approved in Europe for Myeloma

April 3rd 2018

The European Commission has approved denosumab for the prevention of skeletal-related events in adult patients with multiple myeloma.

NEXT PAGE
PREVIOUS PAGE